Catabasis Pharmaceuticals
![]() | This article has multiple issues. Please help or discuss these issues on the . (Learn how and when to remove these template messages)
|
![]() | |
Type | Public |
---|---|
Nasdaq: CATB Russell Microcap Index component | |
Industry | Pharmaceuticals |
Headquarters | Cambridge, Massachusetts |
Key people | Jill C. Milne, Ph.D. (CEO)
Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer) Andrew Nichols, Ph.D. (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer) |
Products | Orally-delivered pharmaceuticals |
Number of employees | 24 (March 2019) |
Website | www.catabasis.com |
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.
In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values [1].
References[]
- ^ "Our Story - Our Company - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
- Biopharmaceutical companies
- Companies listed on the Nasdaq
- Pharmaceutical companies established in 2008
- Health care companies based in Massachusetts
- Companies based in Cambridge, Massachusetts